atenolol has been researched along with Bone Loss, Osteoclastic in 1 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uchibori, S | 1 |
| Sekiya, T | 1 |
| Sato, T | 1 |
| Hayashi, K | 1 |
| Takeguchi, A | 1 |
| Muramatsu, R | 1 |
| Ishizuka, K | 1 |
| Kondo, H | 1 |
| Miyazawa, K | 1 |
| Togari, A | 1 |
| Goto, S | 1 |
1 other study available for atenolol and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Suppression of tooth movement-induced sclerostin expression using β-adrenergic receptor blockers.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Bone Morphogenetic Proteins; Bone Remodeling; Bone R | 2020 |